Patent JPS57120519A successfully refreshed from Google Patents.
US4597960A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Microencapsulated astringent hemostatic agents and methods of use
Assignee: Individual
•
Filing: 1983-06-03
•
Granted: 1986-07-01
•
Expires: 2003-06-03
Abstract
Abstract An astringent hemostatic composition comprised of a micron-sized astringent hemostatic agent microencapsulated in a biocompatible and non-allergenic hemostatic polymer soluble in body fluids. The composition may be used intraorally or dermatologically. For intraoral purposes, the preferred composition is ferric sulfate microencapsulated in ethyl cellulose material. The composition of the invention may be used in a method for effecting gingival retraction. In the method, the microencapsulated astringent hemostatic composition is introduced into the gingival sulcus and is compacted by the patient biting onto bite registration material. A plurality of different microencapsulated astringent hemostatic agents having different time-release properties may be assembled in a kit form allowing a practitioner to formulate a specific formulation designed to treat a specific injury or condition. An astringent hemostatic composition of the invention may be used in a bandage for covering a wound. In one bandage embodiment, the gauze or sponge pad is sprayed with a biocompatible adhesive onto which a dusting of astringent hemostatic composition of the invention is applied. In a second bandage embodiment, a layer or dusting of astringent hemostatic composition of the invention is sandwiched between an upper and lower gauze or sponge layer. In a third bandage embodiment, an astringent hemostatic composition of the invention is adhered to a transdermal bandage using a biocompatible adhesive.
Inventors
- 👤 Edgar C. Cohen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:06
CPC Classifications
A; A61; A61L; A61L15/00; A61L15/16; A61L15/18; A61K; A61K33/00; A61K33/06; A61K33/24; A61K33/26; A61K9/00; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5036; A61K9/5042; A61K9/5047; A61K9/70; A61L15/22; A61L15/28; A61L2400/00; A61L2400/04
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
34 words
A granular composition for producing capillary hemostasis, comprising: a granular astringent hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with a cellulose-based biocompatible polymer soluble in body fluids.
Claim 2
Dependent Claim
34 words
A granular composition for producing capillary hemostasis, comprising: a granular astringent hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with a cellulose-based biocompatible polymer soluble in body fluids.
Claim 3
Dependent Claim
26 words
A composition as described in claim 1 wherein said astringent hemostatic agent is selected from the group consisting of ferric sulfate, aluminum sulfate, and aluminum chloride.
Claim 4
Dependent Claim
12 words
A composition as described in claim 1 further including encapsulated epinephrine granules.
Claim 5
Dependent Claim
33 words
A kit comprising a plurality of encapsulated astringent hemostatic compositions as described in claim 1 for enabling a practitioner to make a formulation having particular astringent and/or hemostatic properties for a particular treatment.
Claim 6
Dependent Claim
28 words
A kit as described in claim 4 wherein, for a specific astringent hemostatic agent, a plurality of encapsulated astringent hemostatic compositions are provided, each having different time-release properties.
Claim 7
Dependent Claim
75 words
A composition for producing capillary hemostasis comprised of a blend in the proportions as follows: particles of astringent hemostatic agent selected from the group consisting of ferric sulfate, aluminum sulfate, and aluminum chloride encapsulated with cellulose-based materials selected from the group consisting of ethyl cellulose, methyl cellulose, oxycellulose, and oxidized cellulose 82-100% and; particles of epinephrine encapsulated with cellulose-base materials selected from the group consisting of ethyl cellulose, methyl cellulose, oxycellulose, and oxidized cellulose 0-18%.
Claim 8
Dependent Claim
75 words
A composition for producing capillary hemostasis comprised of a blend in the proportions as follows: particles of astringent hemostatic agent selected from the group consisting of ferric sulfate, aluminum sulfate, and aluminum chloride encapsulated with cellulose-based materials selected from the group consisting of ethyl cellulose, methyl cellulose, oxycellulose, and oxidized cellulose 82-100% and; particles of epinephrine encapsulated with cellulose-base materials selected from the group consisting of ethyl cellulose, methyl cellulose, oxycellulose, and oxidized cellulose 0-18%.
Claim 9
Dependent Claim
77 words
A composition for producing capillary hemostasis comprised of a blend in the percentages as follows: particles of astringent hemostatic agent selected from the group consisting of ferric sulfate, aluminum sulfate, and aluminum chloride encapsulated with cellulose-based materials selected from the group consisting of ethyl cellulose, methyl cellulose, oxycellulose, and oxidized cellulose about 92% and, particles of epinephrine encapsulated with cellulose-based materials selected from the group consisting of ethyl cellulose, methyl cellulose, oxycellulose, and oxidized cellulose remainder 8%.
Claim 10
Dependent Claim
77 words
A composition for producing capillary hemostasis comprised of a blend in the percentages as follows: particles of astringent hemostatic agent selected from the group consisting of ferric sulfate, aluminum sulfate, and aluminum chloride encapsulated with cellulose-based materials selected from the group consisting of ethyl cellulose, methyl cellulose, oxycellulose, and oxidized cellulose about 92% and, particles of epinephrine encapsulated with cellulose-based materials selected from the group consisting of ethyl cellulose, methyl cellulose, oxycellulose, and oxidized cellulose remainder 8%.
Claim 11
Dependent Claim
57 words
A composition for producing capillary hemostasis, comprising: particles of astringent hemostatic agents selected from the group consisting of ferric sulfate, aluminum sulfate, and aluminum chloride encapsulated with cellulose-base materials selected fom the group consisting of ethyl cellulose, methyl cellulose, oxycellulose and oxidized cellulose; said particles suspended in a liquid carrier which does not dissolve said encapsulation material.
Claim 12
Dependent Claim
57 words
A composition for producing capillary hemostasis, comprising: particles of astringent hemostatic agents selected from the group consisting of ferric sulfate, aluminum sulfate, and aluminum chloride encapsulated with cellulose-base materials selected fom the group consisting of ethyl cellulose, methyl cellulose, oxycellulose and oxidized cellulose; said particles suspended in a liquid carrier which does not dissolve said encapsulation material.
Claim 13
Dependent Claim
34 words
A composition for producing capillary hemostasis, comprising: a granular astringent hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with a cellulose-based biocompatible hemostatic polymer soluble in body fluids.
Claim 14
Dependent Claim
34 words
A composition for producing capillary hemostasis, comprising: a granular astringent hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with a cellulose-based biocompatible hemostatic polymer soluble in body fluids.
Claim 15
Dependent Claim
30 words
A granular composition for producing capillary hemostasis, comprising: a granular hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with ethyl cellulose having hemostatic properties.
Claim 16
Dependent Claim
30 words
A granular composition for producing capillary hemostasis, comprising: a granular hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with ethyl cellulose having hemostatic properties.
Claim 17
Dependent Claim
34 words
A granular composition for producing capillary hemostasis, comprising: a granular astringent hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with a cellulose-based biocompatible polymer absorbable in body fluids.
Claim 18
Dependent Claim
34 words
A granular composition for producing capillary hemostasis, comprising: a granular astringent hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with a cellulose-based biocompatible polymer absorbable in body fluids.
Claim 19
Dependent Claim
34 words
A composition for producing capillary hemostasis, comprising: a granular astringent hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with a cellulose-based biocompatible hemostatic polymer absorbable in body fluids.
Claim 20
Dependent Claim
34 words
A composition for producing capillary hemostasis, comprising: a granular astringent hemostatic agent selected from the group consisting of ferric and aluminum inorganic salts encapsulated with a cellulose-based biocompatible hemostatic polymer absorbable in body fluids.
References Cited (Backward Citations)
US2371862A
Cited
US3238620A
Cited
US3873588A
Cited
US3538214A
Cited
US4268496A
Cited
US4102806A
Cited
US4276287A
Cited
US4166108A
Cited
US4146605A
Cited
US4260597A
Cited
US4395398A
Cited
US4329333A
Cited
US4486412A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-06-30 | 1989-12-30 | 1990-07-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-06-30 | 1993-12-30 | 1994-07-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-06-30 | 1997-12-30 | 1998-07-01 | $7700.00 | Window Closed / Lapsed |